[go: up one dir, main page]

MA50201B1 - Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants - Google Patents

Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Info

Publication number
MA50201B1
MA50201B1 MA50201A MA50201A MA50201B1 MA 50201 B1 MA50201 B1 MA 50201B1 MA 50201 A MA50201 A MA 50201A MA 50201 A MA50201 A MA 50201A MA 50201 B1 MA50201 B1 MA 50201B1
Authority
MA
Morocco
Prior art keywords
delayed
methods
deferipron
tablets
release tablets
Prior art date
Application number
MA50201A
Other languages
English (en)
Other versions
MA50201A (fr
Inventor
Michael Spino
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of MA50201A publication Critical patent/MA50201A/fr
Publication of MA50201B1 publication Critical patent/MA50201B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques, telles que des comprimés, qui présentent des propriétés de libération retardée lorsqu'elles sont administrées sous la forme de demi comprimés ou de comprimés entiers. L'invention concerne également des comprimés à libération retardée comprenant de la défériprone pour une administration orale, pour lesquels une administration quotidienne en deux fois est bioéquivalente à la même dose quotidienne d'un comprimé à libération immédiate administré quotidiennement en trois fois. L'invention concerne également des procédés de fabrication et d'utilisation associés.
MA50201A 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants MA50201B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762577055P 2017-10-25 2017-10-25
US201762596043P 2017-12-07 2017-12-07
EP18871663.3A EP3684344B1 (fr) 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
PCT/IB2018/058350 WO2019082128A1 (fr) 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Publications (2)

Publication Number Publication Date
MA50201A MA50201A (fr) 2021-04-28
MA50201B1 true MA50201B1 (fr) 2025-07-31

Family

ID=66170815

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50201A MA50201B1 (fr) 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Country Status (29)

Country Link
US (8) US20200253945A1 (fr)
EP (2) EP3684344B1 (fr)
JP (1) JP7246384B2 (fr)
KR (1) KR102624627B1 (fr)
CN (2) CN111918646B (fr)
AU (1) AU2018357350B2 (fr)
BR (1) BR112020008128A2 (fr)
CA (2) CA3077514C (fr)
DK (1) DK3684344T3 (fr)
ES (1) ES3036967T3 (fr)
FI (1) FI3684344T3 (fr)
HR (1) HRP20251151T1 (fr)
IL (2) IL321388A (fr)
LT (1) LT3684344T (fr)
MA (1) MA50201B1 (fr)
MD (1) MD3684344T2 (fr)
MX (1) MX2020004107A (fr)
MY (1) MY204588A (fr)
NZ (2) NZ763555A (fr)
PH (1) PH12020550815A1 (fr)
PL (1) PL3684344T3 (fr)
PT (1) PT3684344T (fr)
RS (1) RS67157B1 (fr)
SA (1) SA520411808B1 (fr)
SG (1) SG11202003153TA (fr)
SI (1) SI3684344T1 (fr)
SM (1) SMT202500358T1 (fr)
UA (1) UA126977C2 (fr)
WO (1) WO2019082128A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077514C (fr) 2017-10-25 2022-10-11 Chiesi Farmaceutici S.P.A. Comprimes de deferiprone a liberation retardee et procedes d'utilisation correspondants
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2023198640A1 (fr) 2022-04-11 2023-10-19 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques à libération modifiée comprenant de la défériprone
CN119300809A (zh) 2022-04-11 2025-01-10 奇斯药制品公司 包含去铁酮的调节释放药物制剂
CN120076797A (zh) * 2022-10-14 2025-05-30 奇斯药制品公司 包含去铁酮的调释药物制剂
WO2024240775A1 (fr) 2023-05-25 2024-11-28 Chiesi Farmaceutici S.P.A. Formes galéniques pharmaceutiques pour libération pulsatile

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
US5747532A (en) 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9625638D0 (en) 1996-12-10 1997-01-29 Cenes Ltd Therapeutic antioxidants for alzheimer's diease
WO2001049266A2 (fr) 1999-12-30 2001-07-12 Gwathemy Judith K Systeme de distribution de chelateur de fer
CA2313270C (fr) * 2000-06-30 2011-09-13 Apotex Inc. Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
AU2003251920A1 (en) 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2003282337B2 (en) 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
JP2008509149A (ja) * 2004-08-06 2008-03-27 シバ バイオメディカル，エルエルシー 造影剤の注入を受けるヒトの処置方法
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
AU2007219009B2 (en) 2006-02-22 2012-12-20 Apotex Technologies Inc. The use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
EP2063871A1 (fr) * 2006-08-30 2009-06-03 Jagotec AG Formulations posologiques solides à libération contrôlée administrées par voie orale contenant de la nisoldipine
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080138440A1 (en) * 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
CN101352438A (zh) 2007-07-25 2009-01-28 复旦大学 去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途
EA022751B1 (ru) 2008-04-25 2016-02-29 Апотекс Текнолоджиз Инк. Жидкая композиция деферипрона с замаскированным вкусом
US20110189260A1 (en) 2008-05-30 2011-08-04 University Of Cincinnati Use of zinc chelators to inhibit biofilm formation
WO2010005851A1 (fr) 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Polythérapie destinée au traitement de troubles du fer
US20100255082A1 (en) * 2008-07-31 2010-10-07 Ishwar Chauhan Functionally Coated Breakable Tablets
EP2206506A1 (fr) 2008-12-18 2010-07-14 Bracco Imaging S.p.A Formulations probiotiques
AP2011005843A0 (en) 2009-01-26 2011-08-31 Joshua Lawrence Dunaief Use of deferiprone for treatment and prevention ofiron-related eye disorders.
US8603814B2 (en) 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US20120172292A1 (en) 2009-09-10 2012-07-05 New York University Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
US8563035B2 (en) * 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
JP2014501784A (ja) * 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
DE102011112898A1 (de) * 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
EP2780012A4 (fr) 2011-11-18 2015-07-29 Apotex Technologies Inc Procédés de traitement avec du défériprone
WO2013139931A1 (fr) 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens
MX2015003729A (es) * 2012-11-12 2015-06-15 Cipla Ltd Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona.
AU2014264421A1 (en) * 2013-05-10 2015-12-03 Cipla Limited Low dose pharmaceutical composition
EP3003328B1 (fr) 2013-06-06 2021-07-28 Albion Laboratories, Inc. Supplément de fer
ITMI20132066A1 (it) 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
JP7125396B2 (ja) 2016-08-05 2022-08-24 アブフェロ ファーマシューティカルズ，インコーポレイテッド 金属誘発性疾患を治療するための投与レジメン
US20180362228A1 (en) 2017-02-16 2018-12-20 Jeffrey D. Jacobson Container closure with integrated utensil
CA3077514C (fr) 2017-10-25 2022-10-11 Chiesi Farmaceutici S.P.A. Comprimes de deferiprone a liberation retardee et procedes d'utilisation correspondants

Also Published As

Publication number Publication date
ES3036967T3 (en) 2025-09-25
FI3684344T3 (fi) 2025-10-08
US11357731B2 (en) 2022-06-14
US10940115B2 (en) 2021-03-09
MX2020004107A (es) 2020-07-24
MA50201A (fr) 2021-04-28
US20200253945A1 (en) 2020-08-13
DK3684344T3 (da) 2025-08-04
US11458103B2 (en) 2022-10-04
CA3077514C (fr) 2022-10-11
CA3077514A1 (fr) 2019-05-02
IL273955B1 (en) 2025-07-01
MY204588A (en) 2024-09-05
SG11202003153TA (en) 2020-05-28
US10780055B2 (en) 2020-09-22
KR20200077542A (ko) 2020-06-30
CN111918646A (zh) 2020-11-10
EP3684344B1 (fr) 2025-07-02
US11607389B2 (en) 2023-03-21
NZ787785A (en) 2025-11-28
AU2018357350B2 (en) 2023-09-21
SA520411808B1 (ar) 2023-02-16
US20200188309A1 (en) 2020-06-18
JP7246384B2 (ja) 2023-03-27
CN114533689A (zh) 2022-05-27
SI3684344T1 (sl) 2025-09-30
HRP20251151T1 (hr) 2025-12-05
EP3684344A1 (fr) 2020-07-29
US10940116B2 (en) 2021-03-09
UA126977C2 (uk) 2023-03-01
PH12020550815A1 (en) 2021-07-05
US20220265559A1 (en) 2022-08-25
IL273955B2 (en) 2025-11-01
CN111918646B (zh) 2022-02-22
WO2019082128A1 (fr) 2019-05-02
IL273955A (en) 2020-05-31
US20200268672A1 (en) 2020-08-27
BR112020008128A2 (pt) 2020-11-03
MD3684344T2 (ro) 2025-09-30
US20200237674A1 (en) 2020-07-30
EP4635573A2 (fr) 2025-10-22
CA3172668A1 (fr) 2019-05-02
PL3684344T3 (pl) 2025-10-27
PT3684344T (pt) 2025-08-04
RS67157B1 (sr) 2025-09-30
IL321388A (en) 2025-08-01
EP3684344A4 (fr) 2020-11-18
US20190117581A1 (en) 2019-04-25
LT3684344T (lt) 2025-09-10
KR102624627B1 (ko) 2024-01-16
US20190125682A1 (en) 2019-05-02
SMT202500358T1 (it) 2025-11-10
US20210386677A1 (en) 2021-12-16
JP2021500377A (ja) 2021-01-07
AU2018357350A1 (en) 2020-04-30
US11723874B2 (en) 2023-08-15
NZ763555A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
WO2017141104A8 (fr) Procédé d'induction d'une réponse immunitaire prolongée
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
MA45625A (fr) Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
EP3908251A4 (fr) Compositions d'administration de produits pharmaceutiques et utilisations correspondantes
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EP4048276A4 (fr) Formulations pharmaceutiques solides comprenant du ticagrelor
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
EP3843785A4 (fr) Compositions comprenant des stimulants de la perméation pour l'administration de médicaments
MX2023000479A (es) Composiciones farmaceuticas orales hinchables.
JP2017052778A5 (fr)
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
EA202090842A1 (ru) Таблетки деферипрона с отсроченным высвобождением и способы их применения
WO2020044114A3 (fr) Composition pharmaceutique de méthotrexate
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
EP3841108A4 (fr) Compositions pharmaceutiques comprenant des peptides favorisant l'intégration
MA43793B1 (fr) Procédé de préparation de formulations solides de mésalazine
WO2019004984A3 (fr) Formulation pharmaceutique comprenant du cholécalciférol